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A rare pathway of HIV-1 resistance to small molecule CCR5 inhibitors such as Vicriviroc (VCV) involves
changes solely in the gp41 fusion peptide (FP). Here, we show that the G516V change is critical to VCV
resistance in PBMC and TZM-bl cells, although it must be accompanied by either M518V or F519I to
have a substantial impact. Modeling VCV inhibition data from the two cell types indicated that G516V
allows both double mutants to use VCV-CCR5 complexes for entry. The model further identiﬁed F519I
as an independent determinant of preference for the unoccupied, high-VCV afﬁnity form of CCR5. From
inhibitor-free reversion cultures, we also identiﬁed a substitution in the inner domain of gp120, T244A,
which appears to counter the resistance phenotype created by the FP substitutions. Examining the
interplay of these changes will enhance our understanding of Env complex interactions that inﬂuence
both HIV-1 entry and resistance to CCR5 inhibitors.
& 2012 Elsevier Inc. All rights reserved.Introduction
Maraviroc (MVC, Selzentry; Pﬁzer, Inc.) is the ﬁrst, and so far
only, small molecule CCR5 inhibitor to be approved for treating
HIV-1 infection (MacArthur and Novak, 2008). Vicriviroc (VCV,
Schering-Plough Research Institute; now Merck Research Labora-
tories) is an investigational compound whose development was
abandoned because it did not meet primary efﬁcacy endpoints
in late stage clinical trials. The small molecule CCR5 inhibitors
all impede the coreceptor engagement step of the HIV-1 entry
process via a noncompetitive or allosteric mechanism. To do so,
they bind in a hydrophobic pocket within the CCR5 transmem-
brane helices, stabilizing the receptor in a conformation that is
not recognized efﬁciently by the HIV-1 envelope (Env) glycopro-
tein, gp120 [reviewed in Kuhmann and Hartley, 2008].
The genetic plasticity of HIV-1 allows it to become resistant to
antiretroviral drugs in vitro and in vivo, the CCR5 inhibitors being
no exception. Escape mutants arise when the virus is cultured
for prolonged periods in the presence of these compounds. The
genetic and phenotypic changes that take place in vitro are
similar to those seen in resistant viruses that emerge in patients
[reviewed in Moore and Kuritzkes, 2009]. Virologic failure in vivo
often involves the expansion of pre-existing, CXCR4-using virusesll rights reserved.
gy and Immunology, Weill
enue, Box 62, New York, NY
oore).that are naturally insensitive to CCR5 inhibitors (Westby et al.,
2006). However, resistant variants can also emerge de novo.
Sometimes the escape pathway involves coreceptor switching,
the virus now entering cells via CXCR4, but more usually the
resistant variant acquires the ability to use the drug-bound
conformation of CCR5 (Moore and Kuritzkes, 2009).
The determinants of resistance generally map to the V3 region
of gp120 (Baba et al., 2007; Berro et al., 2012; Kuhmann et al.,
2004; Laakso et al., 2007; Ogert et al., 2008, 2010; Tsibris et al.,
2008; Westby et al., 2007). This region plays a role in CCR5
binding but can tolerate a considerable range of sequences with-
out loss of function (Hartley et al., 2005; Kuhmann and Hartley,
2008). Four V3 substitutions (K305R, H308P, A316V and G321E)
were, for example, responsible for the resistant phenotype of
isolate CC101.19 when the CCR5-using virus CC1/85 was cultured
with the small molecule CCR5 inhibitor AD101 (Kuhmann et al.,
2004; Trkola et al., 2002). A much rarer, indeed to date unique,
route to resistance was undertaken by viruses derived from
the same CC1/85 lineage in an AD101/VCV selection culture
(Marozsan et al., 2005). The D101.12 escape mutants contained
at least one substitution in V3 (H308P) as well as either of the
following combinations of substitutions within and immediately
downstream of the gp41 fusion peptide (FP): G514VþV535M or
M518VþF519LþV535M (Anastassopoulou et al., 2011). We have
also described a VCV escape pathway for viruses from the
D1/85.16 lineage that involved no V3 changes; instead, resistance
mapped to three conservative substitutions in the FP: G516V,
M518V and F519I (Anastassopoulou et al., 2009). The phenylalanine
C.G. Anastassopoulou et al. / Virology 428 (2012) 86–97 87(F) residue at position 519 can change either to isoleucine (I) or to
leucine (L) depending on the resistance pathway (Anastassopoulou
et al., 2011, 2009). Here, we have studied the pathway including the
F519I change.
Unlike a clone derived from CC101.19 (V3 mutations), the
D1/85.16 cl.23 virus (FP mutations) did not have an increased
dependency on the CCR5 N-terminus, and its CCR5 binding site was
not obviously more exposed (Berro et al., 2009). The FP-mutant
was, however, atypically sensitive to a CCR5 monoclonal antibody
(MAb) that stains discrete cell surface clusters of CCR5 that might
correspond to lipid rafts (Berro et al., 2011). Nevertheless, the
precise mechanism by which the FP changes confer resistance
remains to be determined. To better understand the latter escape
mechanism, and also Env structure–function relationships that
inﬂuence HIV-1 entry and its inhibition, we have now studied the
effects of the three FP sequence changes, individually and in
combination.
Here, we report that the G516V change is critical to VCV
resistance, although it must be accompanied by either M518V or
F519I to have a substantial impact. Thus, two different double
mutants are partially resistant, but all three FP changes are
required for complete resistance. During reversion cultures with-
out VCV, the only time the complete cluster of three FP changes
persisted was within the genetic context of a gp120 derived from
the reference resistant clone of this lineage, D1/85.16 cl.23.
However, the FP changes were then accompanied by a substitu-
tion in the inner domain of gp120, T244A, that is part of a
b-sandwich structure involved in gp41 interactions (Finzi et al.,
2010; Pancera et al., 2010; Yang et al., 2003). The emergence
of the T244A change counters the VCV-resistance phenotype
created by the FP substitutions. These ﬁndings add to the com-
plexity of inter-subunit interactions within the Env complex and
may eventually help our understanding of how FP mutations can
confer CCR5 inhibitor resistance.Results
Two pair-wise combinations of FP changes confer partial resistance
to VCV in PBMC
We have shown that the VCV-resistant phenotypes of the
HIV-1 R5 primary isolate D1/85.16, and viruses derived from it,
were attributable to three conservative sequence changes (G516V,
M518V and F519I) in the gp41 FP (Anastassopoulou et al., 2009).
To further study the effects of these substitutions on VCV sensi-
tivity, we performed site-directed mutagenesis to introduce eachTable 1
Nomenclature and properties of viruses used in this study.
Virus Type
S Parental, VCV-sensitive clone
Sþa Single mutant parental clone
Sþb Single mutant parental clone
Sþc Single mutant parental clone
Sþa,b (.r#) Double mutant parental clone (Clone reversion#)
Sþb,c Double mutant parental clone
Sþa,c (.r#) Double mutant parental clone(Clone reversion#)
Sþa,b,c (.r#) Triple mutant parental clone (Clone reversion#)
R (.r#) VCV-resistant clone (Clone reversion#)
N/A, not applicable.
Clones designated as R.r, Sþa,b.r, Sþa,c.r, and Sþa,b,c.r followed by a number were d
double mutants Sþa,b and Sþa,c and the engineered resistant triple mutant Sþa,b,c,
designation. r# indicates the number of weekly passages the virus was in a reversion c
a Amino acid numbering is based on HXB2 Env.change individually, and in all possible pair-wise combinations, into
the reference parental, VCV-sensitive clone CC1/85 cl.6 (¼S). From
here on, we refer to the G516V, M518V and F519I changes as a, b
and c, respectively (see Table 1 for virus nomenclature). The
mutated coding sequences were reconstituted into replication-
competent viruses, most of which replicated comparably to their
parent. Thus, titers in peripheral blood mononuclear cells (PBMC) on
day 7 post-infection were generally in the range 104–105 TCID50/mL
(3–5 ng/mL of p24 antigen). However, although the double mutant
clone Sþa,c was replication-competent, its titers were consistently
several-fold lower (103–104 TCID50/mL; 3 ng/mL of p24).
All the single and double mutants were tested for VCV
sensitivity in a PBMC infection-inhibition assay, alongside the
reference VCV-sensitive and -resistant clones S and D1/85.16
cl.23 (¼R), and also the engineered, VCV-resistant triple mutant
Sþa,b,c [previously referred to as Sþ3FP, Anastassopoulou et al.,
2009] (Fig. 1). For each virus, we determined the half-maximum
inhibitory concentration (IC50) and the maximum percent inhibi-
tion (MPI) value (Table 2). The dose–response curves of CCR5
inhibitor-resistant viruses are characterized by the ‘‘plateau
effect,’’ i.e., the inability of an inhibitor to reduce infectivity below
a certain threshold value, the MPI. This parameter reﬂects the
relative ability of a virus to use the inhibitor-bound and inhibitor-
free forms of CCR5 for entry; the lower the MPI, the more
efﬁciently a resistant virus uses the inhibitor-CCR5 complex
(Pugach et al., 2007; Westby et al., 2007).
Individually, none of the FP changes had a marked impact on
VCV sensitivity (Fig. 1A). The inhibition curve for the Sþb mutant
(M518V substitution) completely coincided with that of the
sensitive virus S. The curves for mutants Sþa and Sþc were
similar in shape to that for S, and not to the unusual, biphasic
inhibition curves seen with the resistant viruses R and Sþa,b,c (i.e.,
Sþ3FP). We have described and modeled the latter type of curve
previously, noting the substantial inﬂuence of PBMC donors on the
complex curve-shapes that can arise with VCV-resistant viruses
(Anastassopoulou et al., 2011, 2009). In the present study, both R
and Sþa,b,c were substantially inhibited (50–80%) by low VCV
concentrations of 0.3–2 nM (Fig. 1). The MPI values for R and
Sþa,b,c were 76% and 82%, respectively, at a VCV concentration of
1.6 nM, while the corresponding plateau values at higher con-
centrations (440 nM) were 52% and 70% (Fig. 1 and Table 2).
When the PBMC inhibition curves for the single FP mutants
were analyzed in more detail, it was apparent that the G516V
change does confer very low resistance to the Sþa mutant, as
manifested by the marginal (3%) level of replication (MPI¼97%)
that can be detected at high VCV concentrations (up to 5 mM). The
G516V change also causes a leftward shift of the dose–responseEnv origin Engineered FP mutations (aa)
CC1/85 cl.6 N/A
CC1/85 cl.6 G516V
CC1/85 cl.6 M518V
CC1/85 cl.6 F519I
CC1/85 cl.6 G516V, M518V
CC1/85 cl.6 M518V, F519I
CC1/85 cl.6 G516V, F519I
CC1/85 cl.6 G516V, M518V, F519I
D1/85.16 cl.23 N/A
erived from the PBMC cultures in which the reference VCV-resistant clone R, the
correspondingly, were cultured for a prolonged period in the absence of VCV. The
ulture, without an inhibitor present.
Table 2
VCV inhibition of replication of FP mutants in PBMC and TZM-bl cells.a
Virus PBMC TZM-bl VCV phenotype in PBMCb
MPI (%) IC50 (nM) MPI (%) IC50 (nM)
S 100 0.51 99 23 Sensitive
Sþa 97 0.31 99 4.6 Weakly resistant
Sþb 100 0.51 100 10 Sensitive
Sþc 100 0.13 100 1.4 Sensitive
Sþa,b 86 0.36 96 3.0 Intermediately resistant
Sþb,c 100 0.17 100 1.4 Sensitive
Sþa,c 86 0.20 96 1.4 Intermediately resistant
Sþa,b,c 82 0.19 97 1.1 Fully resistant
R 76 0.30 87 4.1 Fully resistant
MPI, maximum percent inhibition.
The changes marked as a, b and c are G516V, M518V and F519I, respectively.
a The model function for inhibition, Q¼(1(1(C/(KdiþC))þwn(C/(22nKdiþ
C))))n100%, was ﬁtted to the average PBMC and TZM-bl cell data (see Figs. 1 and 2),
to determine MPI and IC50 values (see ‘‘Materials and methods’’ and ‘‘Results’’; R
2
values are given in Table 3). The IC50 is deﬁned as the VCV concentration (C) that
yields 50% inhibition (Q). The IC50 therefore applies only when MPI450%; accord-
ingly, it can be substantially larger than the VCV concentration that would inhibit
infection to an extent equal to 50% of the MPI value. MPI is deﬁned as the upper
plateau for sigmoid curves, or as the maximum inhibition value for peaked curves.
b Viruses with MPI values for VCV inhibition in PBMC in the range 90–98% are
arbitrarily deﬁned as weakly resistant, 85–90% as having intermediate resistance,
and o85% fully resistant. The fully resistant viruses, according to this deﬁnition, are
highlighted in bold.
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Fig. 1. Effects of the three FP mutations individually and in combination on VCV
resistance on primary cells. The engineered FP mutant viruses were tested for VCV
sensitivity in a PBMC-based, multi-cycle replication assay. For comparison, the
parental, VCV-sensitive clone S, the VCV-resistant clone R and the engineered
resistant triple mutant Sþa,b,c [previously referred to as Sþ3FP, (Anastassopoulou
et al., 2009)] were also tested in the same experiments. Each experiment was
performed on a pool of PBMC from two individuals. For clarity, the dose–response
curves are shown in separate panels for (A) single and (B) double FP mutants. The
results shown are the average of 7–10 independent experiments each performed
using triplicate wells, with the error bars indicating the SEM.
C.G. Anastassopoulou et al. / Virology 428 (2012) 86–9788curve and, thus, a slight reduction in IC50 compared to the
sensitive, virus S (0.31 nM vs. 0.51 nM, for Sþa and S, respec-
tively; Fig. 1A and Table 2). The F519I substitution causes a more
pronounced leftward shift and a further reduction in the IC50
value (0.13 nM vs. 0.51 nM, for Sþc and S, respectively), but
without affecting the MPI value (¼100%) (Fig. 1A and Table 2).
The Sþc mutant is clearly a VCV-sensitive virus, indeed one that
is hypersensitive to low VCV concentrations (0.3–2 nM) com-
pared to Sþa, Sþb and S (Fig. 1A).
Although all three FP changes are required for complete
VCV-resistance, two double mutants, Sþa,b and Sþa,c (changes
G516VþM518V and G516VþF519I, respectively), were partially
resistant (Fig. 1B). Thus, these viruses both had MPI values of 86
and plateau values (see Methods) of 81 at VCV concentrations
above 40 nM (Fig. 1B and Table 2). At low concentrations
(0.3–2 nM), the third substitution, F519I, confers an increase
in VCV sensitivity; thus under these conditions, Sþa,c is more
sensitive than Sþa,b (IC50 0.20 vs. 0.36 nM, respectively). TheSþb,c virus is VCV-sensitive but its IC50 was reduced to 0.17 nM,
presumably due to the impact of the F519I change.
Overall, the G516V change appears to play the most important
role in VCV-resistance; when it is accompanied by either of the
M518V or F519I substitutions, the resulting virus is signiﬁcantly,
but incompletely, resistant. All three FP changes are required for
complete resistance.
FP changes that confer partial VCV-resistance have cell
type-dependent effects
To further study the phenotype conferred by FP changes, we
tested the replication-competent single and double mutants for VCV
resistance in TZM-bl cells, again in comparison to the reference
parental and VCV-resistant clones S and R, and the engineered
resistant triple mutant Sþa,b,c (Fig. 2). The target cell is a known
inﬂuence on how resistance to small molecule CCR5 inhibitors is
manifested, particularly MPI values (Anastassopoulou et al., 2011,
2009; Ogert et al., 2008; Pugach et al., 2007; Westby et al., 2007).
Furthermore, the differences between the MPI values of
VCV-resistant and -sensitive viruses are generally much smaller in
cell lines engineered to express CCR5, such as TZM-bl, than in PBMC
(Anastassopoulou et al., 2011, 2009). The VCV-resistant viruses
carrying FP changes also have paradoxically lower IC50 values than
wild-type viruses, particularly in TZM-bl cells. Hence although by
one measure (MPI) the FP-mutant viruses display a modest level
of resistance in TZM-bl cells, by another (IC50) they appear to be
hypersensitive (Anastassopoulou et al., 2011, 2009). Our present
results are consistent with these earlier ﬁndings in this regard.
In the TZM-bl cell assay, the VCV sensitivity proﬁles of the
single FP mutants were similar to those seen in PBMC, with a few
exceptions. As before, the G516V change in the Sþa mutant
caused a leftward shift of the inhibition curve and a consequent
IC50 reduction compared to S (4.6 nM vs. 23 nM; Fig. 2 and
Table 2). The very low level, but consistently observed, replication
of the Sþa mutant at very high VCV concentrations in PBMC
(MPI¼97%) was not seen with TZM-bl cells (MPI¼99%; Table 2).
-2 -1 0 1 2 3 4
-25
0
25
50
75
100
S
R
S+a
S+b
S+cS+a,b,c
log [Vicriviroc (nM)]
In
hi
bi
tio
n 
(%
)
-2 -1 0 1 2 3 4
-25
0
25
50
75
100
S
R
S+a,cS+a,b,c
S+b,c
S+a,b
log [Vicriviroc (nM)]
)
%(
noitibih nI
Fig. 2. Determinants of VCV resistance in TZM-bl cells. The same clonal viruses
studied in PBMC were assessed for VCV sensitivity in a TZM-bl cell-based, single-
cycle infection assay. For clarity, the dose–response curves are shown in separate
panels for (A) single and (B) double FP mutants. The results shown are the average
of 3 independent experiments, with the error bars indicating the SEM.
C.G. Anastassopoulou et al. / Virology 428 (2012) 86–97 89The Sþb mutant was clearly VCV-sensitive in TZM-bl cells, albeit
with a reduced IC50 compared to S (10 nM vs. 23 nM; Fig. 2 and
Table 2). Among the three FP changes, F519I caused the biggest
leftward shift of the dose–response curve, and thus the greatest
reduction in IC50 (1.4 nM for Sþc vs. 23 nM for S; Fig. 2 and
Table 2). Nonetheless, Sþc was completely sensitive to VCV in
TZM-bl cells, just as it was in PBMC (MPI¼100% in both cell types;
Figs. 1, 2 and Table 2).
The VCV sensitivity proﬁles for the double FP mutants were
similar in TZM-bl cells and PBMC. Thus, the MPI values of 96% in
the TZM-bl cells were consistently below 100% for both Sþa,b
and Sþa,c, indicating that a very low level of replication could
still occur at high inhibitor concentrations. The paradoxical
reductions in IC50 values in TZM-bl cells were again seen for both
double mutants (3.0 nM and 1.4 nM for Sþa,b and Sþa,c vs.
23 nM for S; Fig. 2 and Table 2). Similar phenotypes were also
observed when the corresponding Env-pseudotyped viruses were
tested in U87.CD4.CCR5 cells (data not shown). The F519I change
caused the most pronounced leftward shift in the dose–response
curves in both PBMC and TZM-bl cells, and consequently the
greatest IC50 reductions (Figs. 1 and 2). Thus, as in PBMC, Sþb,c
was a fully sensitive virus (MPI¼100%) in TZM-bl cells, with areduced IC50 compared to S (1.4 nM vs. 23 nM) that reﬂected the
inﬂuence of the F519I change (Figs. 1 and 2 and Table 2).
Modeling VCV resistance of FP mutants
We applied a previously described model (Anastassopoulou
et al., 2009) to VCV inhibition data derived from both PBMC
and TZM-bl cells. The model is a quantitative formulation of the
hypothesis that two distinct forms of CCR5 with high or low
afﬁnity for VCV exist in varying proportions on the surfaces of
different cell types. The inhibition of viral infectivity, Q, is a
function of the VCV concentration, C, according to the equation:
Q ¼ ð1ð1ðC=ðKdiþCÞÞþwnðC=ðKdeþCÞÞÞÞn100%
where Kdi is the postulated dissociation constant for any VCV
binding that blocks viral usage of CCR5, and Kde, is the correspond-
ing constant for any binding that allows the coreceptor still to be
used. The w term reﬂects the relative abundance of the CCR5 form
that can bind VCV with low afﬁnity, and also the efﬁcacy with
which a resistant virus can use that form of CCR5 when it is
complexed with VCV. According to the model, a VCV-sensitive virus
may be able to use both the high- and low-afﬁnity forms of CCR5 to
various extents when they are unoccupied, whereas resistant
viruses use preferentially the unoccupied high-afﬁnity receptor
and the occupied low-afﬁnity receptor (Anastassopoulou et al.,
2009). As previously described, resistant viruses are characterized
by w40 (large values on PBMC, small on TZM-bl cells) and lower
Kdi values than apply to sensitive viruses on TZM-bl cells.
To investigate whether these two features of the resistant pheno-
type could be attributed to different changes in the FP, we modeled
VCV inhibition data derived using the nine viruses described above
and both PBMC (means of 7–10 replicates) and TZM-bl cells (means
of 3 replicates). Nine VCV concentrations were used in the titrations,
and the modeling was based on values calculated from 963 individual
inhibition data points (a single outlying value was censored from this
matrix). Even so, the data were insufﬁcient to determine all three
parameters (w, Kdi and Kde) simultaneously with acceptable precision.
Therefore, and also to make the w and Kd values comparable across
the panel of viruses, we set the ratio of Kde/Kdi to 22, a value between
previous estimates and one that was amenable to good ﬁts for all
resistant viruses (Anastassopoulou et al., 2011, 2009). All the resulting
non-linear regression ﬁts (Prism, Graphpad) yielded R2 values 40.9,
in most cases 1 (Table 3).
The modeling results for the reference viruses S and R reproduce
what we reported previously (Anastassopoulou et al., 2011, 2009).
Thus, w¼0 for S, and w was substantial for R in both cell types but
larger for PBMC than TZM-bl cells (Table 3). In comparison, the
three single-point mutants and the Sþb,c double mutant gave w
values of 0 or close to it (only for the Sþa single mutant were w
values marginally, but consistently, above 0). The Sþa,b and Sþa,c
double mutants and the Sþa,b,c triple mutant all reproduced the R
phenotype, with w40 to different extents. The Kdi values were less
variable from virus to virus with PBMC than TZM-bl cells. On both
cell types, the greatest differences in Kdi compared to the S virus
were seen with Sþc and all the other mutants containing the F519I
change (i.e., mutation-c). In contrast, the Kdi value for the single
Sþb mutant was the most similar to that for S.
These results indicate that the capacity of VCV-resistant
viruses to use VCV-CCR5 complexes is separable genetically from
their apparent preference for using unoccupied forms of CCR5
that have higher afﬁnities for VCV, as depicted graphically in
Fig. 3. Thus, the G516V change (i.e., mutation-a) is a crucial but
insufﬁcient contributor to the usage of VCV-CCR5 complexes
(Fig. 3A); the F519I mutation (i.e., mutation-c) is an independent
determinant of preference for the unoccupied high-afﬁnity form
of CCR5 (Fig. 3B). The M518V (i.e., mutation-b) and F519I changes
FP Mutant Env 
with
a,b; a,c; or a,b,c 
CCR5-A CCR5-B
Low-drug affinity High-drug affinity 
FP Mutant Env
with
c
CCR5-A
CCR5-B
High-drug affinity
Low-drug affinity
Fig. 3. Pictorial model of the usage of different CCR5 conformations by VCV-
resistant FP mutants. CCR5 at the cell surface is postulated to exist in two distinct
forms that could be conformers (conformational isomers) or differentially tyr-
osine-sulfated forms. The two forms of the coreceptor, CCR5-A (black) and CCR5-B
(gray), are assumed to bind small molecule CCR5 inhibitors such as VCV with low
and high afﬁnity, respectively. According to the model (Anastassopoulou et al.,
2009), wild-type virus cannot enter via the VCV-complexes of either CCR5-A or
CCR5-B, although it can use both forms of unligated CCR5 for entry, possibly with
a preference between them. (A) The VCV-resistant FP mutant virus (trimeric Env
sketched in gray on top) has acquired the ability to use speciﬁcally the
VCV-complex of CCR5-A. The sequence changes that allow for the speciﬁc usage
of CCR5-A complexed with VCV involve either two double FP combinations (a,b or
a,c), or all three FP changes (a,b,c; i.e. G516V, M518V and F519I, respectively).
(B) Mutation-c (F519I) confers or enhances the capacity of resistant virus also to
enter via the unligated form of CCR5-B. The VCV-resistant FP mutant virus cannot
use the unligated form of CCR5-A. This ﬁgure is adapted from Fig. S5 of
Anastassopoulou et al. (2009).
Table 3
Modeling VCV inhibition of viral usage of two hypothetical forms of CCR5.
Virus: S R Sþa Sþb Sþc Sþa,b Sþb,c Sþa,c Sþa,b,c
PBMC
Kdi
a 0.5270.051 0.2970.074 0.3170.021 0.5170.11 0.1370.010 0.3570.034 0.1770.042 0.1570.052 0.1870.066
w b 070.016 0.4770.037 0.03370.011 070.037 070.011 0.1970.015 070.036 0.1570.050 0.3070.050
R2 c 0.99 0.90 1.0 0.98 1.0 0.99 0.97 0.92 0.90
TZM-bl
Kdi
a 2475.1 4.070.40 4.770.51 1071.5 1.470.039 3.070.13 1.470.16 1.470.16 1.170.091
w b 070.059 0.1470.020 0.009670.023 070.035 0.002170.0051 0.04170.0086 070.021 0.03570.020 0.03370.014
R2 c 0.98 1.0 0.99 0.99 1.0 1.0 0.99 0.99 1.0
a Modeled dissociation constants, Kdi, have the dimension of concentration (nM). The values are not measurements of afﬁnity: That is only one interpretation under the
simplest assumptions in the model, as explained (Anastassopoulou et al., 2009).
b Values of wZ20% of that for R virus on the respective cells are in italics; values lower than that are given in bold.
c R2 describes the goodness of the ﬁt of the model function, Q¼(1(1(C/(KdiþC))þwn(C/(22nKdiþC))))n100%, by non-linear regression.
C.G. Anastassopoulou et al. / Virology 428 (2012) 86–9790can both synergize with G516V to confer the ability to use VCV-CCR5
complexes. When M518V is added to the other two changes, it has
an incremental effect on the capacity to use VCV-CCR5 complexes on
PBMC. We conclude that M518V and F519I complement the G516V
substitution in qualitatively distinct ways, but together the three
changes largely recreate the VCV-resistance phenotype of the refer-
ence virus, R.Stability of the VCV-resistant phenotypes of FP mutants in the
absence of the inhibitor
The genetic routes to VCV resistance may involve solely V3
changes [as in isolate CC101.19, Kuhmann et al., 2004]; solely FP
changes [as in isolate D1/85.16, Anastassopoulou et al., 2009]; or
a combination of substitutions in gp41 acting in concert with at
least the H308P change in V3 [as in resistant viruses from the
D101.12 lineage, Anastassopoulou et al., 2011]. But whatever
pathway was taken, the resulting isolates all have highly stable
VCV-resistance phenotypes in PBMC, with no apparent ﬁtness
loss (Anastassopoulou et al., 2011, 2009, 2007). Here, we have
assessed the stability of individual clones of the D1/85.16 lineage.
We returned the VCV-resistant reference clone R, the engi-
neered triple mutant Sþa,b,c and the two intermediately resis-
tant double mutants Sþa,b and Sþa,c to culture in PBMC for 10
weekly passages without VCV. The inhibitor sensitivity of replica-
tion-competent viruses derived from the four reversion cultures
was assessed in TZM-bl cells in comparison to clones S and R and
the corresponding input viruses (Fig. 4). The model function
was ﬁtted to the average inhibition data to determine MPI and
IC50 values (Fig. 4 and Table 1S). To track genetic changes, we
sequenced the env genes from all ten passages of the four
reversion cultures (Fig. 5). In a few instances, it was not possible
to retrieve phenotypic or genotypic data during passage 1,
possibly due to a ‘‘bottleneck effect’’ caused by the return to
culture of frozen virus stocks. After the ﬁrst passage, replication
became more consistently efﬁcient.
The VCV inhibition proﬁles of the reference clones S and R
were similar to those seen before in TZM-bl cells; for R, the MPI
and IC50 values were lower than for S (91–94% vs. 100% and
1.4–2.2 nM vs. 8.5-16 nM, respectively; Fig. 4, Table 1S). The
inhibition curves for viruses from passages 1–4 of the R virus
reversion culture overlapped. Compared to R, the MPI values for
these viruses were modestly reduced from 90% to 85–86% while
the IC50 values gradually increased from 2.2 nM to 4.0 nM (Fig. 4A
and Table 1S). From passage 5 on, the dose–response curves
shifted up- and rightwards, leading to increasing MPI and IC50
values that peaked at 97% and 8.3 nM for virus R.r7. Thus the
viruses from the reversion culture of clone R became gradually
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Fig. 4. VCV-sensitivity in TZM-bl cells of the VCV-resistant FP mutants after extensive passage in PBMC in the absence of the inhibitor. Viruses designated (clone name).
r1–r10 were derived from the reversion cultures of: (A) the VCV-resistant reference clone R; (B) the engineered VCV-resistant triple mutant Sþa,b,c; the two intermediately
resistant double FP mutants (C) Sþa,b and (D) Sþa,c. Each virus was assessed for VCV sensitivity in TZM-bl cells in comparison to clones S and R and the corresponding
input resistant virus, with luciferase expression measured after 3 days. The results shown are the average of 2–5 (typically 3) independent experiments, with the error bars
indicating the SEM.
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to use the VCV-CCR5 complex for entry.
Genetic sequencing showed that all three FP sequence changes
persisted throughout the 10 passages of the R virus reversion
culture (Fig. 5A). However, by passage 5, an additional Thr-to-Ala
substitution had become stabilized at position 244 of the second
conserved region (C2) of gp120. This residue is located in strand
b7, part of a b-sandwich structure in the inner domain that is
involved in CD4-induced conformational changes within gp120
and the interaction with gp41 (Finzi et al., 2010; Helseth et al.,
1991; Pancera et al., 2010; Yang et al., 2003). Once it emerged, the
T244A substitution persisted together with the 3FP changes. Thus,
2/10 clones from passage 4, 11/12 clones from passage 5 and all
11 clones from passage 9 contained the T244A change (Fig. 5A).
We describe below studies on the phenotype conferred by the
T244A substitution.Several other amino acid changes also appeared elsewhere
in Env as the R virus reversion culture progressed. In particular,
three different passage 9 clones contained one of the V3 sub-
stitutions T303A, F315L or T317A in addition to the three FP
changes (data not shown). The most inﬂuential resistance-asso-
ciated change in the FP, mutation-a, had reverted to the cognate
amino acid residue (V516G) in 1/12 passage 5 clones, R.r5 cl.11,
but all 11 clones from virus R.r9 retained the three FP
substitutions.
Stability of the engineered VCV resistant triple mutant Sþa,b,c
On addition to the reversion culture, Sþa,b,c again had an MPI
value marginally below 100% and a reduced IC50 value of 0.7 nM
(compared to 2.2 nM for R and 16 nM for S) (Fig. 4B, Table S1, see
also Fig. 2, Table 2). Viruses from passages 2 and 3 had much
Fig. 5. Env sequence alignments of viruses derived from the reversion cultures of VCV-resistant FP mutants. The ﬁrst 23 amino acids from the gp41 N-terminus are shown
for viruses derived from the 10 weekly VCV-free passages in PBMC of: (A) the reference clone R (D1/85.16 cl.23, GenBank accession no. FJ713453); (B) the triple mutant
Sþa,b,c; the double FP mutants (C) Sþa,b and (D) Sþa,c. Additional regions where differences were noted, i.e. either in the C2 of gp120 or further downstream in gp41, are
shown for R and Sþa,c, respectively. Passage 1 sequence data were unavailable for Sþa,b,c and Sþa,c. Amino acid sequences are also shown for 10 clones from passage 4,
for 12 clones from passage 5 and for 11 clones from passage 9 of the clone R reversion culture. No gp41 sequence data were obtained for the 10 clones from passage 4 and
for clone R.r9 cl.39, as indicated by the dashes in the alignment. The bulk sequences of the reversion isolates are highlighted in bold, while those of individual clones are
shown in regular fonts. The sequences are recorded relative to that of the reference parental clone S (CC1/85 cl.6, GenBank accession no. AY357338, top line), with dots
indicating amino acid sequence identity. Amino acid numbering is based on HXB2 Env, with the ﬁrst residue of gp41 at position 512.
C.G. Anastassopoulou et al. / Virology 428 (2012) 86–9792lower MPI values of 79–80% and modestly higher IC50 values of
1.6 nM. The pattern then changed from passage 4 onwards; the
later viruses had gradually increasing MPI values that peaked at
94% by passage 7. The IC50 values also tended to rise over time in
culture, reaching 7.1 nM by passage 10 (Fig. 4B and Table S1).
In contrast to the R virus reversion culture, the three FP
changes were maintained only during the ﬁrst two VCV-free
passages of Sþa,b,c (Fig. 5B). Mutation-c was the ﬁrst to dis-
appear, during the third passage, followed by mutation-a by the
ﬁfth passage; mutation-b, however, remained stable during all
ten passages. A transient replacement of Ala by Ser at position
533 of gp41 during passage 4 (indicated by X in Fig. 5B) coincided
temporally with an increase in MPI from 79% to 86% between
passages 3 and 4 (Figs. 4B, 5B and Table S1).Stability of the double mutants, Sþa,b and Sþa,c
At the start of the reversion cultures, the double FP mutants
Sþa,b and Sþa,c had MPI values of 99% and 98%, respectively,
which were higher than the 96% values seen previously in TZM-bl
cells (Fig. 4C, D, Table S1, and Fig. 2, Table 2). The MPI for clone R
was also higher in this experiment than previously (94% com-
pared to 91% in the other two reversion cultures and 87% in
previous experiments, Fig. 4, Table S1, and Fig. 2, Table 2). The
IC50 values for Sþa,c and Sþa,b (0.5 vs. 2.6 nM, respectively)
were comparable to those obtained previously (1.4 vs. 3.0 nM;
Figs. 4C, D, Table S1 and Fig. 2, Table 2).
Only minor changes in VCV sensitivity occurred during the
Sþa,b reversion culture. By passage 10, the MPI and IC50 values
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Fig. 6. VCV-sensitivity of viruses from the reversion culture of clone R in a PBMC
assay. Viruses derived from the PBMC reversion culture of clone R were tested for
VCV sensitivity in a PBMC-based, multi-cycle replication assay in comparison to
the parental, VCV-sensitive clone S and the VCV-resistant reference clone R. Each
infection-inhibition experiment was performed on a pool of PBMC from two
individuals. The results shown are the average of 2–6 (typically 4) independent
experiments, each performed using triplicate wells, with the error bars indicating
the SEM. No data were obtained for virus R.r1.
C.G. Anastassopoulou et al. / Virology 428 (2012) 86–97 93for the Sþa,b.r10 virus were 97% and 6.8 nM, indicating a modest
decrease in MPI and a slight (3-fold) increase in IC50 compared
to Sþa,b (Fig. 4C and Table S1). As seen in the corresponding
experiments with R and Sþa,b,c, mutation-b remained stable
throughout the Sþa,b culture, while mutation-a had disappeared
by the fourth passage (Fig. 5C). Thus, at the end of this culture, the
Sþa,b.r10 virus was genetically and phenotypically similar to
Sþb (see Table 2).
Initial bottleneck events in the Sþa,c reversion culture led to a
further suppression of the MPI to 72–74% and an increase in the IC50
up to 4.2 nM by passage 3 (Fig. 4D and Table S1). The VCV dose–
response curves of the passage 4–6 viruses resembled that for R,
with similar MPI (92–93%) and IC50 values (1.1–1.8 nM), but from
passage 7 onwards, the inhibition curves tended to shift only right-
wards. The MPI values were maintained at 94–95% but with increas-
ing IC50 values that peaked at 7.6 nM during the tenth passage. Again,
the critical resistance mutation, a, reverted rapidly, in this case by
passage 3, even more quickly than in the corresponding cultures of
Sþa,b (passage 4) and Sþa,b,c (passage 5) (Fig. 5B and D). Mutation-c
had disappeared by passage 6, later than in the Sþa,b,c culture
(passage 3). Two new gp41 mutations V703A and W755R, located in
the transmembrane region and the cytoplasmic tail, appeared during
passage 4 but they were sustained only for one and two more
passages, respectively (Fig. 5D). The transient appearance of these
mutations coincided with substantial shifts in the inhibition curves,
irrespective of whether mutation-c was present in the FP.
In summary, the reversion experiments show that mutation-b,
a naturally occurring polymorphism that becomes enriched under
VCV or AD101 selection pressure (Anastassopoulou et al., 2009),
remained unaltered throughout the inhibitor-free cultures of each
relevant input virus. This change, M518V, has little or no effect on
VCV sensitivity on its own and appears to be under no pressure to
revert. The complete cluster of three FP changes only persisted
within the genetic context of a gp120 derived from the resistant
clone R. Here, however, they were accompanied by a gp120-C2
substitution, T244A, that appears to counter the VCV-resistance
phenotype created by the FP substitutions.
VCV-sensitivity of reversion viruses of clone R in a PBMC assay
We also used the more physiologically relevant, multi-cycle
PBMC assay to study replication-competent viruses R.r2-r10 from
the R virus reversion culture (Fig. 6). Samples of virus R.r1 were
unavailable for testing. To determine MPI and IC50 values, the model
function was ﬁtted to the average VCV-inhibition data (Table S1).
Viruses R.r2-r10 replicated comparably to R, with PBMC titers of
104–105 TCID50/mL (3–5 ng/mL of p24) on day 7 post-infection.
Taking into account PBMC donor-dependent inﬂuences on the
biphasic VCV-inhibition curves for resistant viruses, clone R behaved
comparably to what was seen previously in this assay (compare
Fig. 6, Table S1 with Fig. 1, Table 2). Thus, clone R had lower MPI
and IC50 values than S (73% and 0.55 nM vs. 100% and 0.74 nM,
respectively). During the reversion culture, the shapes of the
VCV-inhibition curves gradually shifted to more closely resemble S
than R, although the process appeared to be somewhat more
complex in this multi-cycle replication system than in the TZM-bl-
based single-cycle assay (Fig. 6 cf. Fig. 4A). The curves for R.r2-R.r4
were all similar in shape to R with MPI values that ranged from 69%
to 77%, but those for R.r3 and R.r4 were shifted to the left such that
the IC50 values were reduced to 0.25–0.27 nM (Fig. 6 and Table S1).
From passage 5 onwards, the curves gradually shifted upwards and
rightwards, generating MPI and IC50 values that peaked at 91% and
1.1 nM for virus R.r8. An exception to this pattern was R.r9, in that it
resembled clone R by having a similar MPI value, albeit accompa-
nied by an increased IC50 value (76% and 2.8 nM compared to 73%
and 0.55 nM, respectively; Fig. 6 and Table S1).Effects of the T244A change on resistance of FP mutants
To study the T244A substitution, we introduced it into the
VCV-sensitive clone S and the resistant triple mutant Sþa,b,c and
tested the resulting replication-competent viruses for VCV sensi-
tivity in PBMC and TZM-bl cells. The T244A mutation reduced the
PBMC titers of the parental clone S by several-fold (103–104
compared to 104–105 TCID50/mL). The Sþa,b,c mutant was little
affected by the T244A change, with both viruses replicating in the
103–104 TCID50/mL range.
The Sþa,b,cþT244A mutant was VCV-sensitive in a PBMC-
based multi-cycle assay. Thus, whereas the VCV-inhibition curve
for Sþa,b,c has a complex shape, the one for Sþa,b,cþT244A
resembles the parental clone S (Fig. 7A). The corresponding MPI
values were 83% and 100% (Table 2S). The inhibition curves for
Sþa,b,cþT244A and Sþa,b,c were both still shifted to the left
compared to S (IC50 values 0.18 nM and 0.24 nM vs. 0.95 nM),
presumably due to the inﬂuence of mutation-c.
In the TZM-bl cell assay, the inhibition curve for Sþa,b,cþ
T244A was shifted to the right and slightly upward compared
to Sþa,b,c, yielding increased IC50 and MPI values (1.5 nM vs.
0.54 nM and 100% vs. 98%) (Fig. 7B and Table S2). Similar results
were obtained when AD101 was used instead of VCV (data not
shown). By itself, the T244A change modestly (2 fold) reduced
the IC50 for VCV when introduced into clone S (0.50 nM vs.
0.95 nM for SþT244A vs. S in PBMC; 5.8 nM vs. 11 nM, respec-
tively, in TZM-bl cells).Discussion
In vitro resistance to small molecule CCR5 inhibitors, such as
MCV and VCV, principally stems from an acquired ability of HIV-1
to utilize the drug-bound form of the coreceptor for entry in
addition to free CCR5. The mutations that allow this to happen
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Fig. 7. The T244A change compromises the VCV-resistance phenotype created by
the FP mutations. Replication-competent viruses from the VCV-sensitive clone S
and the VCV-resistant triple mutant Sþa,b,c were tested for VCV sensitivity in
comparison to the corresponding viruses harboring the T244A change in gp120-C2
using (A) PBMC and (B) TZM-bl cells. The VCV-resistant clone R was also tested in
the same experiments. Each infection-inhibition experiment on PBMC was
performed on a pool of cells from two individuals. The results shown are the
average of 2–5 (typically 3) independent experiments in each assay system, each
performed using triplicate wells, with the error bars indicating the SEM.
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2009). However, we have described two alternative routes to
resistance. One involved at least an H308P change in V3 and
either of the following combinations of gp41 changes: G514Vþ
V535M or M518VþF519LþV535M (Anastassopoulou et al., 2011).
In the other, three sequence changes (G516V, M518V and F519I) in
the gp41 FP were sufﬁcient for resistance (Anastassopoulou et al.,
2009).
We have now studied how the above three FP sequence
changes (termed a, b, and c here), individually and in combina-
tion, affect VCV sensitivity. Although mutation-a (G516V) confers
only a very low level of VCV resistance by itself, an effect evident
in PBMC but not TZM-bl cells, it is critical overall. To have a
substantial impact, mutation-a must be accompanied by either of
the other two FP substitutions. Thus, both the Sþa,b and Sþa,c
double mutants are partially VCV-resistant, but only the Sþa,b,c
triple mutant is fully resistant. No naturally occurring viruses in
the HIV Sequence Database (http://www.hiv.lanl.gov/, updated
as of 1/30/2012) contain all three FP changes, although somesubtype B and C strains have the aþb (G516VþM518V)
combination.
These above two changes are both present in isolate Du151
from a South African who was dually infected with two phylo-
genetically distinct subtype C strains. During disease progression
in this patient, a coreceptor switch to CXCR4 use was associated
with speciﬁc amino acid changes in the V3 crown, an increased
net charge in V3, and an increase in the length of V1 (Coetzer
et al., 2007). Together with several other changes scattered
throughout Env, the G516VþM518V combination was also pre-
sent in 8/12 clones at the time of virologic failure (compared to
0/12 at baseline) in a previously treatment-naı¨ve, subtype
B-infected patient given the CCR5 inhibitor, aplaviroc, in combi-
nation with lopinavir-ritonavir (Kitrinos et al., 2009). This patient
underwent a phenotypic switch from R5 to dual/mixed during
treatment. The G516V change (mutation-a) by itself has been
shown to confer CXCR4 usage on a clonal R5 virus (Huang et al.,
2008).
Taken together, these various reports imply that FP changes
are associated with, and may facilitate, tropism switches from
CCR5 to CXCR4. However, our FP mutants were unable to use
CXCR4 in PBMC or TZM-bl cells (Anastassopoulou et al., 2009).
The implication is that additional changes are required to drive
the virus towards CXCR4, at least in the context of the CC1/85
genetic lineage, which may be predisposed to acquiring resistance
to MCV and other CCR5 inhibitors via an inherent, low-level
ability to use drug-bound CCR5 for entry (Roche et al., 2011).
Further evidence for the relevance of the Env genetic context in
CCR5 inhibitor resistance is that introducing the three FP changes
into a heterologous virus, JR-FL, did not create a VCV-resistant
variant (Anastassopoulou et al., 2009). Nonetheless, the presence
of the Val-516 and Val-518 polymorphisms in natural viruses
further implies that these residues are compatible with the
normal functioning of the FP, despite their rarity compared to
Gly-516 and Met-518.
Modeling the VCV inhibition data derived from both PBMC and
TZM-bl cells conﬁrmed the crucial role of mutation-a; only the
Sþa single mutant yielded w-values that were marginally, but
consistently, above 0. The model further showed that combining
mutation-a with either mutation-b or mutation-c conferred the
ability to use VCV-CCR5 complexes for entry. Hence, the Sþa,b
and Sþa,c double mutants and the Sþa,b,c triple mutant all
reproduced the R phenotype to various extents, with w40.
The ability of the escape mutants to use the inhibitor-bound
form of CCR5 for entry, in addition to the inhibitor-free form, is
consistent with noncompetitive resistance [reviewed in Kuhmann
and Hartley, 2008; Moore and Kuritzkes, 2009]. Competitive
resistance results in a shift in the IC50 of an inhibitor to a higher
concentration, with complete inhibition potentially achievable at
a high enough inhibitor concentration. In contrast, for a non-
competitive resistance mechanism, the IC50 values are typically
equivalent to those for the fully sensitive virus but the extent
of inhibition is incomplete. The resulting MPI values vary by
cell type for inhibition by VCV and related compounds
(Anastassopoulou et al., 2011, 2009; Ogert et al., 2008; Pugach
et al., 2007; Westby et al., 2007). The MPI value, at a saturating
inhibitor concentration, reﬂects the efﬁciency with which the
inhibitor-CCR5 complex is used, relative to free CCR5, thereby
providing a measure of the degree of resistance of the HIV-1
variant under study (Pugach et al., 2007; Westby et al., 2007).
It is an apparent paradox that many of the FP mutants have
reduced IC50 values for VCV, particularly in TZM-bl cells but also
on occasions in PBMC. As an explanation, we have proposed that
the resistant FP-mutants switch to use unoccupied forms of CCR5
for which VCV has a higher afﬁnity, compared to the forms the
wild type virus can use (Anastassopoulou et al., 2009). Here, we
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preference for the unoccupied high-afﬁnity form of CCR5. Thus,
the three FP changes combine their qualitatively unique effects to
create an unusual VCV-resistance phenotype.
A recent study showed that three VCV-resistant clinical iso-
lates with V3 mutations had delayed entry rates that were
restored to pre-therapy levels in the presence of the inhibitor
(Putcharoen et al., 2012). The authors suggested that the under-
lying mechanism of resistance to CCR5 antagonists is the need for
HIV-1 to maximize its rate of entry into cells in the context of
both its own genetic background and the properties of the host
cells (e.g., the quantity and properties of the available CCR5
coreceptors). We have yet to examine the fusion efﬁciency and
entry kinetics of the various FP mutants to further explore this
admirable concept.
All the VCV-resistant isolates we studied previously have
highly stable phenotypes in PBMC, in that they do not rapidly
revert to sensitivity when cultured without the inhibitor
(Anastassopoulou et al., 2011, 2009, 2007). Here, we assessed
the stability in PBMC of individual FP mutant clones with various
degrees of VCV-resistance. Mutation-b (M518V), which has little
or no effect on VCV sensitivity by itself, persisted throughout the
reversion cultures, implying that there is no pressure for it
to revert. Val-518 is a naturally occurring FP polymorphism
that becomes enriched during VCV or AD101 selection
(Anastassopoulou et al., 2009). A study of viral diversiﬁcation in
newly infected individuals identiﬁed FP residue 518 as one that
was rapidly evolving (from Met to Val or Ile) under positive
selection, although without any indications for the involvement
of CTL escape or APOBEC hypermutation (Wood et al., 2009).
There were, however, no general indications across multiple
patients that Met was present at residue 518 during acute
infection, but replaced by Val or Ile in chronic infection.
Viruses from the clone R reversion culture gradually became
less able to use the VCV-CCR5 complex for entry from passage
5 onwards. The cluster of three FP changes remained unchanged
throughout this culture, but by passage 5, an additional Thr-to-
Ala substitution had become stabilized at position 244 in the
gp120 C2 region. Once it emerged, the T244A change persisted
together with the 3FP changes. Several other amino acid changes
also appeared in the reversion culture. In particular, three
independent passage 9 clones contained one of the V3 substitu-
tions T303A, F315L, or T317A in addition to the three FP changes
(data not shown). However, these V3 changes probably represent
the detection of minor populations, as they were not found in the
bulk sequence of the passage 9 isolate.
As the genotypic and phenotypic data from the reversion
culture suggested the T244A change counteracted the causative
effect of the three FP changes on VCV resistance, we introduced it
into the resistant triple FP mutant. The resulting Sþa,b,cþT244A
virus was indeed VCV-sensitive in the PBMC-based, multi-cycle
assay. Residue 244 is located in strand b7 of the b-sandwich in
the inner domain of gp120, which is thought to be involved in
transmitting conformational changes from gp120 to gp41 upon
CD4 binding (Finzi et al., 2010; Helseth et al., 1991; Pancera et al.,
2010; Yang et al., 2003). The side chain of residue 244 is solvent
exposed in the crystal structure of the gp120 core that includes
the N- and C-termini, suggesting that it may interact with gp41
directly (Pancera et al., 2010). On its own, but in a different
genetic context, the T244A change drastically reduces virus entry
(Yang et al., 2003). We noted that it did reduce, albeit only by
several-fold, the replication of the reference parental CC1/85
clone (clone S).
A Thr-to-Ser substitution at the same position (T244S) has
been reported to be one of four changes that rescue the replica-
tion capacity of viruses resistant to virus-inhibitory peptide(VIRIP) (Gonzalez-Ortega et al., 2011), an inhibitor corresponding
to the C-proximal region of a1-antitrypsin (Munch et al., 2007).
Viruses resistant to VIRIP and its derivative VIR-353 contain a
combination of three mutations in gp120 (A433T/V489I) and
gp41 (V570I), but no changes in or near the FP (Gonzalez et al.,
2011). Furthermore, sequence variations in the FP were not
responsible for the different virological responses to treatment
with another VIRIP analog, VIR-576 (Forssmann et al., 2010).
Nonetheless, the involvement of position 244 in both VIRIP and
VCV resistance/reversion is worth noting from the perspective of
structure/function relationships in Env that inﬂuence both HIV-1
entry and resistance development.Materials and methods
Reagents
The small molecule CCR5 inhibitors VCV (SCH-D, SCH-417690)
and AD101 (SCH-350581) were provided by Dr. Julie Strizki (Scher-
ing-Plough Research Institute; now Merck Research Laboratories).
Viruses
The clonal viruses listed in Table 1 were designed to investi-
gate individually and in pair-wise combinations the effects of
three FP changes (G516V, M518V, F519I) on the VCV-resistant
phenotype of the D1/85.16 lineage (Anastassopoulou et al., 2009).
Infectious, replication-competent stocks were prepared by tran-
sient transfection of 293T cells with pNL4-3/env proviral plasmids
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. Env-pseudotyped viruses were prepared by
co-transfecting 293T cells with pCI-env and pNLluc-AM plasmids
(3:1 ratio), again using Lipofectamine 2000. All viruses were
used at similar pre-titrated doses (100 50% tissue culture infec-
tive doses (TCID50) per well of a 96-well plate), as described
(Anastassopoulou et al., 2009; Kuhmann et al., 2004).
Construction of chimeric NL4-3/env proviruses and pCI-based
env-expressing plasmids
NL4-3/env proviruses were constructed as previously
described (Anastassopoulou et al., 2009; Kuhmann et al., 2004).
Site-directed mutagenesis was performed with QuickChange II
(Stratagene), using pBluescript KS(þ) plasmids containing EcoRI/
XhoI fragments that were then subcloned into pNL4-3. Mutagen-
esis was similarly performed on a pCI-based plasmid expressing
the env gene of the reference VCV-sensitive clone CC1/85 cl.6
(¼S, GenBank accession no. AY357338). The construction of the
pNLluc-AM and pCI-env plasmids for expression of S has been
described elsewhere (Pugach et al., 2007). Env genes were
sequenced as described (Marozsan et al., 2005; Trkola et al.,
2002) and aligned with MacVector 10.5.1. Env sequences derived
from the reversion cultures of the VCV-resistant clone R (D1/
85.16 cl.23, GenBank accession no. FJ713453), the triple mutant
Sþa,b,c and the double mutants Sþa,b and Sþa,c have been
submitted to GenBank (accession nos. JQ707955–JQ708027).
Infection-inhibition assays
HIV-1 sensitivity to VCV was assessed using primary cells
(PBMC) or engineered cell lines (TZM-bl and U87.CD4.CCR5), as
previously described (Anastassopoulou et al., 2011, 2009; Ketas
et al., 2007; Kuhmann et al., 2004; Marozsan et al., 2005). The
PBMC assay endpoint was p24 production after 7 days of infection.
With TZM-bl and U87.CD4.CCR5 cells, luciferase expression in
C.G. Anastassopoulou et al. / Virology 428 (2012) 86–9796relative light units (RLU) was measured after 2 and 3 days,
respectively. The sensitivity of VCV escape mutants to inhibitors
of post-entry stages of the replication cycle has been evaluated
previously; D101.12 and D1/85.16 and their parental isolates had
comparable sensitivities to the nucleoside reverse transcriptase
inhibitor zidovudine (AZT), the non-nucleoside reverse transcrip-
tase inhibitor nevirapine, the protease inhibitor indinavir and the
integrase inhibitor 118-D-24 (Marozsan et al., 2005).
The model function for inhibition, Q¼(1(1(C/(KdiþC))þ
wn(C/(22nKdiþC))))n100% (Anastassopoulou et al., 2011, 2009;
Ketas et al., 2012; Klasse, 2007), was ﬁtted to the average PBMC
and TZM-bl data by non-linear regression (Prism, Graphpad). The
model function was also ﬁtted by non-linear regression (Prism,
Graphpad) to determine MPI and IC50 (as deﬁned in Tables 2, S1
and S2) as well as the parameters Kdi and w (Table 3). The MPI is
deﬁned as the upper plateau for sigmoid curves, or as the
maximum inhibition value for peaked curves, while the IC50 is
deﬁned as the VCV concentration (C) that yields 50% inhibition
(Q). To generate the VCV-inhibition curves shown in Figs.1, 2, 4,
6 and 7, we used a form of the equation with 10-logarithms of
inhibitor concentrations as x values:
Q ¼ ð1ð1ð10logC=ðKdiþ10logCÞÞ
þwnð10logC=ð22nKdiþ10logCÞÞÞÞn100%,
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